Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7869240 | 0.86 | ALDH1A1 (0.57) | GAATDP1KDM4EMAPTHPGD | |
| SCHEMBL9355162 | 0.83 | GAA (0.62) | GAATDP1KDM4EMAPTHPGD | |
| SCHEMBL3686455 | 0.80 | GAA (0.64) | GAATDP1MAPTHPGDNPC1 | |
| SCHEMBL21465958 | 0.79 | HPGD (0.71) | GAATDP1KDM4EMAPTHPGD | |
| SCHEMBL2683360 | 0.78 | TDP1 (0.57) | GAATDP1KDM4EMAPTHPGD | |
| Hydrochloric Acid SCHEMBL29106619 | 0.77 | HPGD (0.68) | GAATDP1KDM4EMAPTHPGD | |
| SCHEMBL17536014 | 0.76 | MAPT (0.50) | GAATDP1MAPTHPGDALDH1A1 | |
| SCHEMBL7082949 | 0.75 | PTGS2 (0.79) | GAATDP1KDM4EMAPTHPGD | |
| SCHEMBL9224278 | 0.75 | ALDH1A1 (0.51) | GAATDP1MAPTHPGDALDH1A1 | |
| SCHEMBL22043338 | 0.75 | TDP1 (0.46) | GAATDP1KDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677343-B2 | USEFUL IN PROTECTING SKELETAL MUSCLES AGAINST DAMAGE RESULTING FROM TRAUMA OR TO PROTECT AGAINST LIMPING, TREATING SHOCK CONDITIONS, PRESERVE DONOR TISSUE AND ORGANS USED IN TRANSPLANTS, AND IN TREATING CARDIOVASCULAR DISEASES | CV THERAPEUTICS, INC. | 2004-01-13 | — | — | US | disclosed |
| US-20030064994-A1 | Substituted alkyl piperazine derivatives | CV THERAPEUTICS, INC. | 2003-04-03 | — | — | US | disclosed |
| EP-1259493-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6451798-B2 | PROTECTING SKELETAL MUSCLES AGAINST TRAUMA DAMAGE AND SUBSEQUENT TO DISEASE; TREATING SHOCK AND CARDIOVASCULAR DISEASES; PRESERVING DONOR TISSUE AND ORGANS USED IN TRANSPLANTS | CV THERAPEUTICS, INC. | 2002-09-17 | — | — | US | disclosed |
| US-20010047001-A1 | Substituted alkyl piperazine derivatives | CV THERAPEUTICS, INC. | 2001-11-29 | — | — | US | disclosed |
| US-20010044541-A1 | Substituted piperazine compounds | GILEAD PALO ALTO, INC. | 2001-11-22 | — | — | US | disclosed |
| WO-2001062744-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001062749-A1 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047001-A1 | Substituted alkyl piperazine derivatives | ATP2A1, CPT1B, TNNC1 | GAA 1671/4885TDP1 3188/4885KDM4E 3816/4885 |
| US-20010044541-A1 | Substituted piperazine compounds | ATP2A1, CPT1B, TNNC1 | GAA 1569/4885TDP1 3367/4885KDM4E 4437/4885 |
| US-20030064994-A1 | Substituted alkyl piperazine derivatives | ATP2A1, CPT1B, TNNC1 | GAA 1671/4885TDP1 3188/4885KDM4E 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.